<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594111</url>
  </required_header>
  <id_info>
    <org_study_id>CARB-025-15S</org_study_id>
    <nct_id>NCT02594111</nct_id>
  </id_info>
  <brief_title>Colchicine in Percutaneous Coronary Intervention</brief_title>
  <acronym>Colchicine-PCI</acronym>
  <official_title>Anti-inflammatory Therapy During Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation in the arteries of the heart may increase the risk of cardiac death. The
      proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory
      medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of
      the heart. With its quick onset of action and excellent safety profile, colchicine may have
      the potential to reduce risk of major adverse events related to the heart. This research also
      seeks to better understand the role of neutrophils, the most common type of inflammatory
      white blood cell in the body, when there is damage to the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will use colchicine as a tool to elucidate the role of neutrophil
      activation during acute vascular injury, and to explore the association between neutrophil
      activation and adverse cardiovascular outcomes. Colchicine reduces cell surface expression of
      selections, adhesion molecules key to neutrophil recruitment after vascular injury. Daily
      colchicine use is associated with reduced adverse cardiovascular events in stable
      atherosclerosis. Using a clinical percutaneous coronary intervention (PCI) model, the
      investigators evaluate whether pre-procedural colchicine (1.8 mg oral load over one hour)
      reduces the rate of post-PCI adverse cardiovascular outcomes in the context of a double-blind
      placebo-controlled randomized study. The investigators will also characterize neutrophil
      biology in acute vascular injury and the effects of colchicine on neutrophil biology in this
      setting.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2013</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Peri-procedural Myocardial Necrosis</measure>
    <time_frame>24 hours</time_frame>
    <description>troponin above the upper limit of normal (ULN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality, Non-fatal MI, or Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality, Non-fatal MI, or TVR</measure>
    <time_frame>1 year</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality, Non-fatal MI, or TVR</measure>
    <time_frame>2 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality, Non-fatal MI, or TVR</measure>
    <time_frame>3 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality, Non-fatal MI, or TVR</measure>
    <time_frame>4 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality, Non-fatal MI, or TVR</measure>
    <time_frame>5 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Peri-procedural Myocardial Infarction (MI)</measure>
    <time_frame>24 hours</time_frame>
    <description>SCAI definition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">714</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 1.8 mg PO over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine vs Placebo</intervention_name>
    <description>Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referred for possible PCI

        Exclusion Criteria:

          -  Colchicine use within 1 month

          -  History of colchicine intolerance

          -  Glomerular filtration rate &lt;30mL/minute or on dialysis (due to the need to adjust
             colchicine dose in this setting)

          -  Active malignancy or infection (major confounder with increased inflammatory markers)

          -  History of myelodysplasia (due to suggested cautionary use of colchicine in this
             setting)

          -  High-dose statin load &lt;24 hours prior to procedure (major confounder that is known to
             reduce inflammatory levels in 12 to 24 hours)

          -  Use of anti-inflammatory agents (except aspirin) within 5 halflives of the individual
             drug

          -  Use of strong Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 (CYP3A4) and/or
             P-glycoprotein inhibitors (e.g. ritonavir, ketoconazole, clarithromycin, cyclosporine,
             diltiazem and verapamil, again due to drug interactions)

          -  Unable to consent

          -  Participating in a competing study

          -  Any significant condition or situation that may put the subject at higher risk,
             confound the study results or interfere with adherence to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>June 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02594111/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02594111/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colchicine</title>
          <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colchicine</title>
          <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="366"/>
            <count group_id="B2" value="348"/>
            <count group_id="B3" value="714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="9.7"/>
                    <measurement group_id="B2" value="65.8" spread="10.7"/>
                    <measurement group_id="B3" value="65.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="324"/>
                    <measurement group_id="B3" value="660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="521"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Peri-procedural Myocardial Necrosis</title>
        <description>troponin above the upper limit of normal (ULN)</description>
        <time_frame>24 hours</time_frame>
        <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peri-procedural Myocardial Necrosis</title>
          <description>troponin above the upper limit of normal (ULN)</description>
          <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality, Non-fatal MI, or Target Vessel Revascularization (TVR)</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>30 days</time_frame>
        <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality, Non-fatal MI, or Target Vessel Revascularization (TVR)</title>
          <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
          <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality, Non-fatal MI, or TVR</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality, Non-fatal MI, or TVR</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality, Non-fatal MI, or TVR</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality, Non-fatal MI, or TVR</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality, Non-fatal MI, or TVR</title>
        <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Peri-procedural Myocardial Infarction (MI)</title>
        <description>SCAI definition</description>
        <time_frame>24 hours</time_frame>
        <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peri-procedural Myocardial Infarction (MI)</title>
          <description>SCAI definition</description>
          <population>Although 714 patients had baseline measure, were randomized to colchicine or placebo, and underwent coronary angiography, but of these, 400 patients went on to stent placement and had primary outcome measured (as per protocol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days for patients who underwent PCI (24 hours for those who underwent diagnostic angiogram only)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Colchicine</title>
          <description>Colchicine 1.8 mg PO over 1 hour
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo
Colchicine vs Placebo: Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Unrelated to study medication</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="348"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Binita Shah</name_or_title>
      <organization>VA NY Harbor Healthcare System</organization>
      <phone>212-686-7500</phone>
      <email>binita.shah@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

